ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Nature
; 464(7287): 405-8, 2010 Mar 18.
Article
em En
| MEDLINE
| ID: mdl-20173735
ABSTRACT
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirofosfatases
/
Variação Genética
/
Hepatite C Crônica
/
Anemia Hemolítica
Limite:
Humans
País como assunto:
America do norte
/
Europa
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article